Active Filter(s):
Details:
The Series A financing, will support Veralox's efforts to advance the development program for its lead product candidate VLX-1005 for the treatment of heparin-induced thrombocytopenia (HIT).
Lead Product(s): VLX-1005
Therapeutic Area: Hematology Product Name: VLX-1005
Highest Development Status: Phase I Product Type: Small molecule
Partner/Sponsor/Collaborator: Hatteras Venture
Deal Size: $16.6 million Upfront Cash: Undisclosed
Deal Type: Series A Financing June 16, 2021